Skip to main content
. 2020 Jan 21;15(1):e0227557. doi: 10.1371/journal.pone.0227557

Fig 1. Mean change in VA at Month 12 based on baseline VA categories.

Fig 1

A) in treatment-naïve patients with mCNV. B) in prior ranibizumab-treated patients with mCNV. Observed data set for VA change (primary treated eye set). n = number of evaluable patients with baseline and Month 12 data. The mean number of injections from baseline to Month 12 is designated with a syringe ETDRS, Early treatment diabetic retinopathy study; mCNV, myopic choroidal neovascularization; n, number of patients; VA, visual acuity.